Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology - Annual Meeting 2025

Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology - Annual Meeting 2025

MUMBAI, India, NAPLES, Fla. and CHICAGO, May 27, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) annual…

Lupin announces presentation of phase 1 data on LNP7457 (PRMT5 inhibitor) at the ASCO - Annual Meeting 2025 - Express Pharma

Lupin will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, from May 30 to June 3, 2025. The presentation titled “A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumours” will be featured in the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biol…